Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Pemetrexed

Pemetrexed 500 mg/m2 IV q 3 weeks

Trial Locations (16)

19713

Helen F. Graham Cancer Center, Newark

46202

Indiana University Cancer Center, Indianapolis

46256

Community Regional Cancer Center, Indianapolis

46515

Elkhart Clinic, Elkhart

46527

Center for Cancer Care at Goshen Health System, Goshen

46601

Northern Indiana Cancer Research Consortium, South Bend

46617

Northern Indiana Oncology Associates, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47150

Center for Cancer Care, Inc., P.C., New Albany

47303

Medical Consultants, P.C., Muncie

47714

Oncology Hematology Associates of SW Indiana, Evansville

47804

AP&S Clinic, Terre Haute

47904

Arnett Cancer Care, Lafayette

61401

Medical & Surgical Specialists, LLC, Galesburg

63110

Siteman Cancer Center, St Louis

68114

Methodist Cancer Center, Omaha

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Walther Cancer Institute

OTHER

lead

Hoosier Cancer Research Network

OTHER